| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ren2 |
| Uniprot No | P00796 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 64-351aa |
| 氨基酸序列 | SSLTDLISPVVLTNYLNSQYYGEIGIGTPPQTFKVIFDTGSANLWVPSTKCSRLYLACGIHSLYESSDSSSYMENGDDFTIHYGSGRVKGFLSQDSVTVGGITVTQTFGEVTELPLIPFMLAQFDGVLGMGFPAQAVGGVTPVFDHILSQGVLKEKVFSVYYNRGPHLLGGEVVLGGSDPEHYQGDFHYVSLSKTDSWQITMKGVSVGSSTLLCEEGCEVVVDTGSSFISAPTSSLKLIMQALGAKEKRLHEYVVSCSQVPTLPDISFNLGGRAYTLSSTDYVLQYPN |
| 预测分子量 | 35.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ren2重组蛋白的3篇参考文献的简要列举(注：Ren2通常指啮齿类动物中与肾素相关的转基因模型，部分文献可能与重组蛋白应用相关)：
---
1. **文献名称**: *Tissue-specific expression of a renin enhancer/lacZ transgene defined by targeted integration*
**作者**: Sigmund CD, Jones CA, Fabian JR, et al.
**摘要**: 该研究利用转基因技术在小鼠中构建了携带Ren2基因增强子与lacZ报告基因的模型，分析了肾素(Renin)在组织特异性表达中的调控机制，为研究Ren2相关蛋白在心血管系统中的作用提供基础。
---
2. **文献名称**: *The role of the renin-angiotensin system in transgenic Ren-2 rats*
**作者**: Mullins JJ, Peters J, Ganten D
**摘要**: 研究通过转基因Ren2大鼠模型，探讨肾素-血管紧张素系统(RAS)在高血压和器官损伤中的作用，揭示了Ren2重组蛋白过表达导致血管收缩增强和心脏肥大的病理机制。
---
3. **文献名称**: *Recombinant expression and functional characterization of human renin for drug discovery*
**作者**: Wood JM, Schnell CR, Söhngen SM
**摘要**: 描述了人源肾素(Renin)重组蛋白的体外表达与纯化方法，评估其酶活性及在药物筛选中的应用，为开发肾素抑制剂类抗高血压药物提供技术参考(与啮齿类Ren2蛋白功能相关)。
---
**备注**：
- Ren2重组蛋白研究多集中于其转基因动物模型(如大鼠)，直接以“Ren2 recombinant protein”为标题的文献较少，上述文献涉及Ren2基因功能或重组肾素蛋白应用。
- 如需更精准的文献，建议结合具体研究场景(如疾病模型、蛋白结构)进一步筛选。
Ren2 (Renin-2) is a recombinant protein derived from the renin-angiotensin system (RAS), a critical regulator of blood pressure and fluid balance in mammals. Renin, an aspartyl protease, exists in two isoforms (Ren1 and Ren2) in certain species, including mice. While Ren1 is primarily expressed in the kidneys, Ren2 is found in extrarenal tissues like the adrenal glands and brain, with unique species-specific expression patterns. The Ren2 gene gained attention due to its role in transgenic rodent models of hypertension. For instance, insertion of the mouse Ren2 gene into rats (TGR(mRen2)27 strain) induces severe hypertension and organ damage, mimicking human cardiovascular pathologies.
Recombinant Ren2 protein is synthesized using expression systems (e.g., E. coli, mammalian cells) to study RAS activation mechanisms. It catalyzes the cleavage of angiotensinogen to angiotensin I, initiating the cascade leading to vasoconstrictive angiotensin II. Researchers leverage Ren2 to explore tissue-specific RAS activity, as its localized production in organs like the heart or vasculature may drive hypertension and fibrosis independently of circulatory renin. This has implications for understanding resistant hypertension and diabetic complications.
Pharmaceutically, Ren2 serves as a target for renin inhibitors (e.g., aliskiren) and aids in drug screening. Its recombinant form also helps standardize assays measuring renin activity in clinical diagnostics. However, challenges persist in reconciling interspecies differences—human RAS lacks Ren2. complicating translational research. Studies using Ren2 transgenic models continue to unravel its paracrine signaling roles and potential therapeutic interventions. Overall, Ren2 recombinant protein bridges experimental models and clinical insights into RAS-driven diseases.
×
